ProQR Therapeutics (NASDAQ:PRQR) Releases Earnings Results, Beats Estimates By $0.01 EPS

ProQR Therapeutics (NASDAQ:PRQR) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01, FiscalAI reports. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $4.30 million. ProQR Therapeutics had a negative return on equity of 73.83% and a negative net margin of 223.51%.

ProQR Therapeutics Stock Up 9.1%

Shares of PRQR stock traded up $0.12 during trading hours on Thursday, hitting $1.38. 334,152 shares of the company’s stock traded hands, compared to its average volume of 747,607. ProQR Therapeutics has a 12-month low of $1.20 and a 12-month high of $2.48. The stock’s fifty day simple moving average is $1.60 and its two-hundred day simple moving average is $1.68. The stock has a market cap of $144.87 million, a price-to-earnings ratio of -3.01 and a beta of 0.29.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on PRQR shares. Wall Street Zen upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 15th. Bank of America started coverage on shares of ProQR Therapeutics in a research note on Thursday, August 20th. They set a “buy” rating and a $8.00 price target for the company. Weiss Ratings upgraded ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 14th. Citigroup reaffirmed a “market outperform” rating on shares of ProQR Therapeutics in a research note on Thursday, October 1st. Finally, HC Wainwright lowered their price target on shares of ProQR Therapeutics to $8.00 and set a “buy” rating for the company in a research note on Thursday, October 1st. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.60.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a biotechnology company focused on developing RNA therapies for genetic diseases. The company uses its Axiomer RNA-editing platform to investigate treatments designed to correct disease-causing genetic changes at the RNA level without permanently altering DNA. ProQR’s research has included therapies for rare inherited disorders, particularly genetic diseases affecting the eye and nervous system. Its development programs have included investigational treatments for inherited retinal diseases, while the company has also pursued partnerships and licensing opportunities to advance RNA-editing applications across additional disease areas.